Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Afferent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Afferent. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-000474-35 Sponsor Protocol Number: AF219-010 Start Date*: 2015-07-07
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects with Refractory Chronic Cough
    Medical condition: Chronic cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002034-47 Sponsor Protocol Number: AF219-014 Start Date*: 2015-10-12
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects
    Medical condition: Chronic cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024283-18 Sponsor Protocol Number: AF219-006 Start Date*: 2011-05-20
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects with Chronic Cough
    Medical condition: Subjects with Chronic Cough
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002114-11 Sponsor Protocol Number: SER-LEV-2004-01 Start Date*: 2005-05-09
    Sponsor Name:Infociencia Clinical Research
    Full Title: A double blind, randomized, placebo-controlled, cross-over study to evaluate the effects of Levetiracetam on membrane excitability properties of afferent myelinated and unmyelinated fibers and chan...
    Medical condition: Neuropathic pain due to a traumatic nerve lesion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005064-42 Sponsor Protocol Number: AF219-012 Start Date*: 2016-02-26
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A 12-Week Study to Assess the Efficacy and Safety of AF-219 in Subjects with Treatment Refractory Chronic Cough
    Medical condition: Chronic Cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000464-34 Sponsor Protocol Number: AF219-015 Start Date*: 2015-04-29
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects
    Medical condition: Chronic Cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003566-13 Sponsor Protocol Number: AF219-009 Start Date*: 2013-11-06
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to evaluate the effect of AF-219 on methacholine hyper-reactivity in subjects with asthma.
    Medical condition: Stable Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021295-28 Sponsor Protocol Number: ottavi Start Date*: 2010-09-30
    Sponsor Name:AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA
    Full Title: therapy antiedemigena through administration of corticosteroidi after surgical extraction of the teeth of the judgment.
    Medical condition: This study is going to be performed on patients afferent to the service of Chirurgia Maxillo Facciale dell’Ospedale Maggiore della Carita` di Novara subject to eights bony included extraction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042613 SOC
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003029-40 Sponsor Protocol Number: IOBA-01-2016 Start Date*: 2017-02-14
    Sponsor Name:IOBA - University of Valladolid
    Full Title: Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION)
    Medical condition: Non arteritic anterior ischemic optic neuropathy (NAION)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000730-19 Sponsor Protocol Number: DC2019ROCKIES1 Start Date*: 2020-03-05
    Sponsor Name:Amsterdam Univeristy Medical Center - Vu Univeristy Medical Center
    Full Title: A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on re...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023586-22 Sponsor Protocol Number: BAY38-9456/12912 Start Date*: 2012-06-08
    Sponsor Name:Bayer AG
    Full Title: Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
    Medical condition: Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001066-14 Sponsor Protocol Number: DENERVHTA Start Date*: 2012-07-17
    Sponsor Name:Consorci Mar Parc de salut de Barcelona ( Parc de Salut Mar)
    Full Title: Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension
    Medical condition: subjects with resistant hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000655-36 Sponsor Protocol Number: 80684 Start Date*: 2023-04-06
    Sponsor Name:Amsterdam UMC
    Full Title: Evaluation of GeranylGeranylAcetone in heart failure with preserved ejection fraction
    Medical condition: Heart Failure with preserved ejection fraction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004467-50 Sponsor Protocol Number: SFN-3-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with non-diabetic chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004447-80 Sponsor Protocol Number: SFN-2-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with type 2 diabetes and chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Type 2 diabetes with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003730-15 Sponsor Protocol Number: D3601113 Start Date*: 2007-01-09
    Sponsor Name:Dainippon Sumitomo Pharma Europe Ltd.
    Full Title: A 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and ...
    Medical condition: Overactive Bladder Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed) LT (Completed) LV (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000008-34 Sponsor Protocol Number: 07.IBS.1 Start Date*: 2007-09-13
    Sponsor Name:North West London Hospitals NHS Trust
    Full Title: Bacteria and host immune response as factors modulating visceral afferent processing in Irritable Bowel Syndrome: manipulation of visceral hypersensitivity with probiotic bacteria
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003284-19 Sponsor Protocol Number: CTU/2013/073 Start Date*: 2017-01-24
    Sponsor Name:University College London
    Full Title: DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-016038-29 Sponsor Protocol Number: LIDO-2009 Start Date*: 2010-03-11
    Sponsor Name:Danish Pain Research Center
    Full Title: Topical lidocaine: Predictors of response in peripheral nerve damage
    Medical condition: Neuropathic pain due to Peripheral nerve damage
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011302 Peripheral nerve injuries HLT
    12.1 10034586 Peripheral nerve injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:04:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA